LAMAs and ICS-LABA-LAMA combinations approved for asthma treatment in adults and adolescents

Brand name	Active ingredients	Inhaler brand name (type)	Strength (microg)	Maintenance dose
Spiriva*	Tiotropium	Respimat (SMI)	2.5	2 inhalations daily
Enerzair^†	Mometasone-indacaterol-glycopyrronium	Breezhaler (DPI)	68/114/46 136/114/46	2 inhalations per capsule daily
Trelegy^†	Fluticasone furoate-vilanterol-umeclidinium	Ellipta (DPI)	200/25/62.5	1 inhalation daily
Trimbow^†	Beclometasone-formoterol-glycopyrronium	(pMDI)	100/6/10 200/6/10	2 inhalations twice daily

Additional information

DPI: dry powder inhaler; ICS: inhaled corticosteroid; LABA: long-acting beta₂ agonist; ; LAMA: long-acting muscarinic antagonist; pMDI: pressurised metered-dose inhaler; SMI: soft mist inhaler

* Treatment must be used in combination with a maintenance combination of an ICS (at least 800 microg budesonide per day or equivalent) and a LABA, unless a LABA is contraindicated.

† Patient must be at least 18 years of age for all ICS-LABA-LAMA combinations